Image source: Kite Pharma, Inc.Following the release of interim results from a mid stage trial, Kite Pharma, Inc. (NASDAQ: KITE) appears on track to become the first company to launch a chimeric antigen receptor T-cell, or CAR-T, therapy. If so, then the impressive efficacy observed in this trial may revolutionize how doctors tackle tough-to-treat lymphomas.Continue reading